Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: Preliminary findings

Jan Fritz, Eva K. Galeczko, Nina Schwenzer, Michael Fenchel, Claus D. Claussen, John A. Carrino, Marius S. Horger

Research output: Contribution to journalArticle

Abstract

We retrospectively assessed the longitudinal changes of rheumatoid arthritis under rituximab therapy by use of quantitative and dynamic contrast-enhanced 3-T magnetic resonance (MR) imaging of the metacarpophalangeal joints of 10 patients at baseline and 26 weeks (n = 10). Additional studies were available at 12 weeks (n = 9) and at 52 weeks (n = 5). Clinical activity was assessed by use of the 28-joint disease activity score (DAS28). MR imaging was used to assess volumes of synovial enhancement, osseous enhancement, and erosions and early rapid enhancement. DAS28 and serum C-reactive protein trended down over time and were significantly lower at 26 weeks. Volume of synovial enhancement and early rapid enhancement showed a significant minimum at 26 weeks and increased thereafter. The erythrocyte sedimentation rate paralleled these two trends. Osseous enhancement did not significantly change over time. Erosions showed a significant progression. Trends of DAS28 and erosions were significantly different (P = 0.0075). In conclusion, our preliminary results suggest that rituximab is associated with a decrease of the inflammatory activity of synovitis with a minimum at 26 weeks and increasing activity thereafter suggesting recurrence. Our results further suggest subclinical progression of erosions with an inverse relationship to decreasing disease activity scores. Further studies are needed to confirm these results.

Original languageEnglish (US)
Pages (from-to)2217-2224
Number of pages8
JournalEuropean Radiology
Volume19
Issue number9
DOIs
StatePublished - 2009

Fingerprint

Rheumatoid Arthritis
Magnetic Resonance Imaging
Metacarpophalangeal Joint
Synovitis
Joint Diseases
Blood Sedimentation
C-Reactive Protein
Blood Proteins
Recurrence
Rituximab
Therapeutics

Keywords

  • Dynamic contrast-enhanced MR imaging
  • High-field MR imaging
  • Magnetic resonance imaging
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging : Preliminary findings. / Fritz, Jan; Galeczko, Eva K.; Schwenzer, Nina; Fenchel, Michael; Claussen, Claus D.; Carrino, John A.; Horger, Marius S.

In: European Radiology, Vol. 19, No. 9, 2009, p. 2217-2224.

Research output: Contribution to journalArticle

Fritz, Jan ; Galeczko, Eva K. ; Schwenzer, Nina ; Fenchel, Michael ; Claussen, Claus D. ; Carrino, John A. ; Horger, Marius S. / Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging : Preliminary findings. In: European Radiology. 2009 ; Vol. 19, No. 9. pp. 2217-2224.
@article{6e2ebc479f7b42ab944a0c4c757a2c63,
title = "Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: Preliminary findings",
abstract = "We retrospectively assessed the longitudinal changes of rheumatoid arthritis under rituximab therapy by use of quantitative and dynamic contrast-enhanced 3-T magnetic resonance (MR) imaging of the metacarpophalangeal joints of 10 patients at baseline and 26 weeks (n = 10). Additional studies were available at 12 weeks (n = 9) and at 52 weeks (n = 5). Clinical activity was assessed by use of the 28-joint disease activity score (DAS28). MR imaging was used to assess volumes of synovial enhancement, osseous enhancement, and erosions and early rapid enhancement. DAS28 and serum C-reactive protein trended down over time and were significantly lower at 26 weeks. Volume of synovial enhancement and early rapid enhancement showed a significant minimum at 26 weeks and increased thereafter. The erythrocyte sedimentation rate paralleled these two trends. Osseous enhancement did not significantly change over time. Erosions showed a significant progression. Trends of DAS28 and erosions were significantly different (P = 0.0075). In conclusion, our preliminary results suggest that rituximab is associated with a decrease of the inflammatory activity of synovitis with a minimum at 26 weeks and increasing activity thereafter suggesting recurrence. Our results further suggest subclinical progression of erosions with an inverse relationship to decreasing disease activity scores. Further studies are needed to confirm these results.",
keywords = "Dynamic contrast-enhanced MR imaging, High-field MR imaging, Magnetic resonance imaging, Rheumatoid arthritis, Rituximab",
author = "Jan Fritz and Galeczko, {Eva K.} and Nina Schwenzer and Michael Fenchel and Claussen, {Claus D.} and Carrino, {John A.} and Horger, {Marius S.}",
year = "2009",
doi = "10.1007/s00330-009-1401-y",
language = "English (US)",
volume = "19",
pages = "2217--2224",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging

T2 - Preliminary findings

AU - Fritz, Jan

AU - Galeczko, Eva K.

AU - Schwenzer, Nina

AU - Fenchel, Michael

AU - Claussen, Claus D.

AU - Carrino, John A.

AU - Horger, Marius S.

PY - 2009

Y1 - 2009

N2 - We retrospectively assessed the longitudinal changes of rheumatoid arthritis under rituximab therapy by use of quantitative and dynamic contrast-enhanced 3-T magnetic resonance (MR) imaging of the metacarpophalangeal joints of 10 patients at baseline and 26 weeks (n = 10). Additional studies were available at 12 weeks (n = 9) and at 52 weeks (n = 5). Clinical activity was assessed by use of the 28-joint disease activity score (DAS28). MR imaging was used to assess volumes of synovial enhancement, osseous enhancement, and erosions and early rapid enhancement. DAS28 and serum C-reactive protein trended down over time and were significantly lower at 26 weeks. Volume of synovial enhancement and early rapid enhancement showed a significant minimum at 26 weeks and increased thereafter. The erythrocyte sedimentation rate paralleled these two trends. Osseous enhancement did not significantly change over time. Erosions showed a significant progression. Trends of DAS28 and erosions were significantly different (P = 0.0075). In conclusion, our preliminary results suggest that rituximab is associated with a decrease of the inflammatory activity of synovitis with a minimum at 26 weeks and increasing activity thereafter suggesting recurrence. Our results further suggest subclinical progression of erosions with an inverse relationship to decreasing disease activity scores. Further studies are needed to confirm these results.

AB - We retrospectively assessed the longitudinal changes of rheumatoid arthritis under rituximab therapy by use of quantitative and dynamic contrast-enhanced 3-T magnetic resonance (MR) imaging of the metacarpophalangeal joints of 10 patients at baseline and 26 weeks (n = 10). Additional studies were available at 12 weeks (n = 9) and at 52 weeks (n = 5). Clinical activity was assessed by use of the 28-joint disease activity score (DAS28). MR imaging was used to assess volumes of synovial enhancement, osseous enhancement, and erosions and early rapid enhancement. DAS28 and serum C-reactive protein trended down over time and were significantly lower at 26 weeks. Volume of synovial enhancement and early rapid enhancement showed a significant minimum at 26 weeks and increased thereafter. The erythrocyte sedimentation rate paralleled these two trends. Osseous enhancement did not significantly change over time. Erosions showed a significant progression. Trends of DAS28 and erosions were significantly different (P = 0.0075). In conclusion, our preliminary results suggest that rituximab is associated with a decrease of the inflammatory activity of synovitis with a minimum at 26 weeks and increasing activity thereafter suggesting recurrence. Our results further suggest subclinical progression of erosions with an inverse relationship to decreasing disease activity scores. Further studies are needed to confirm these results.

KW - Dynamic contrast-enhanced MR imaging

KW - High-field MR imaging

KW - Magnetic resonance imaging

KW - Rheumatoid arthritis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=68449098691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449098691&partnerID=8YFLogxK

U2 - 10.1007/s00330-009-1401-y

DO - 10.1007/s00330-009-1401-y

M3 - Article

C2 - 19396446

AN - SCOPUS:68449098691

VL - 19

SP - 2217

EP - 2224

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 9

ER -